From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies

The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However, the remaining limitations concerning the graft-versus-host disease (GVHD) and other adverse effects (e.g., cytokine release s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Hui, Zhao, Xiaoyan, Li, Ziying, Hu, Yu, Wang, Huafang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377427/
https://www.ncbi.nlm.nih.gov/pubmed/34422667
http://dx.doi.org/10.3389/fonc.2021.720501

Ejemplares similares